secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001615219-25-000004
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius to merge with Decoy; Decoy valued at $28M, legacy holders ~14.1% ownership
--------------------------------------------------------------------------------

- Merger structured as stock-for-stock with Decoy valued at $28M and Salarius at $4.6M, based on cash at close.
- Legacy Salarius stockholders retain ~14.1%; Decoy stockholders own ~85.9% of combined company.
- Closing conditioned on minimum $6M Qualified Financing and continued Nasdaq listing.
- Combined company to focus on Decoy's IMP3ACT peptide platform, SP-3164 P-PROTACs; initial targets antivirals and CRC.
- Salarius paid $350K to cancel a warrant for 454,546 shares; SP-2577 program remains on partial clinical hold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000004/0001615219-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000004/flks-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer